We think this is a good move for Johnson and Johnson. It boosts their pharmaceutical (sales) growth also brings them expertise in research and development of drug delivery.

These are dedicated doctors, who take care of very sick patients. It's a doctor's duty to care. Care in the field doesn't change.

Physicians themselves haven't lost anything. As long as revenue is there, they're getting paid.

The company gave me confidence that they have next-generation products for markets that they currently participate in. Additionally, for the large markets where they are not players, the company is developing compounds.

We have now registered our fourth consecutive quarter of strong sales growth and our third consecutive quarter of higher earnings, excluding special items,

We're very encouraged by the growth in digital sales. And while international sales still has a ways to go, there is a lot of upside.